Cheung Kong trials CK Life

Investor presentations begin in Singapore next Tuesday for Li Ka-shing''s latest investment vehicle, Cheung Kong Life Sciences.

A roughly $300 million GEM listing for the biotech arm of the Cheung Kong empire is already starting to whip up a media frenzy and lead manager Salomon Smith Barney is undoubtedly hoping that retail investors are about to shortly follow suit.

All commentators agree that while the 1.3 billion share deal has the outward appearance of a standard IPO, it is in reality little more than a branding exercise for the Li family name, with a highly...

To continue reading, please login or register for free

Click for more on: cheung | kong | trials | ck | life

Print Edition

FinanceAsia Print Edition